[1]刘艳,吴晓宇,刘少稳.节律控制在心房颤动治疗中的作用[J].国际心血管病杂志,2022,03:137-140.
点击复制
节律控制在心房颤动治疗中的作用(PDF)
《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]
- 期数:
- 2022年03期
- 页码:
- 137-140
- 栏目:
- 综述
- 出版日期:
- 2022-06-20
文章信息/Info
- Title:
- -
- Author(s):
- -
- Keywords:
- -
- 分类号:
- -
- DOI:
- 10.3969/j.issn.1673-6583.2022.03.003
- 文献标识码:
- -
- 摘要:
- 心房颤动（房颤）的节律控制是指通过心脏电复律、抗心律失常药物和（或） 导管消融治疗恢复和长期维持窦性心律。研究发现，房颤患者早期节律控制可改善心血管预 后，为房颤治疗策略提供了新的思路。
- Abstract:
- -
参考文献/References
[1] Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines
for the diagnosis and management of atrial fibrillation
developed in collaboration with the European Association for
Cardio-Thoracic Surgery (EACTS): The Task Force for the
diagnosis and management of atrial fibrillation of the European
Society of Cardiology (ESC) developed with the special
contribution of the European Heart Rhythm Association
(EHRA) of the ESC[J]. Eur Heart J, 2021, 42(5):373-498.
[2] Du X, Guo L, Xia S, et al. Atrial fibrillation prevalence,
awareness and management in a nationwide survey of adults
in China[J]. Heart, 2021, 107(7):535–541.
[3] Kirchhof P, Camm A J, Goette A, et al. Early rhythm-control
therapy in patients with atrial fibrillation[J]. N Engl J Med,
2020, 383(14):1305-1316.
[4] Nattel S, Guasch E, Savelieva I, et al. Early management of
atrial fibrillation to prevent cardiovascular complications[J].
Eur Heart J, 2014, 35(22):1448-1456.
[5] Vlachos K, Letsas KP, Korantzopoulos P, et al. Prediction
of atrial fibrillation development and progression: current
perspectives[J]. World J Cardiol, 2016, 8(3):267-276.
[6] Zhang YY, Qiu C, Davis PJ, et al. Predictors of progression
of recently diagnosed atrial fibrillation in REgistry on
Cardiac Rhythm DisORDers Assessing the Control of Atrial
Fibrillation (RecordAF)-United States cohort[J]. Am J Cardiol,
2013, 112(1):79-84.
[7] Suman-Horduna I, Roy D, Frasure-Smith N, et al. Quality of
life and functional capacity in patients with atrial fibrillation
and congestive heart failure[J]. J Am Coll Cardiol, 2013,
61(4):455-460.
[8] Ullah W, Ling L H, Prabhu S, et al. Catheter ablation of atrial
fibrillation in patients with heart failure: impact of maintaining
sinus rhythm on heart failure status and long-term rates of
stroke and death[J]. Europace 2016, 18(5):679-686.
[9] Kosior DA, Szulc M, Rosiak M, et al. Functional status
with rhythm- versus rate-control strategy for persistent atrial
fibrillation[J]. Pol Arch Intern Med, 2018, 128(11):658-666.
[10] Connolly SJ, Crijns HJ, Torp-Pedersen C, et al. Analysis
of stroke in ATHENA: a placebo-controlled, double-blind,
parallel-arm trial to assess the efficacy of dronedarone 400 mg
BID for the prevention of cardiovascular hospitalization or
death from any cause in patients with atrial fibrillation/atrial
flutter[J]. Circulation, 2009, 120(13):1174-1180.
[11] Friberg L, Tabrizi F, Englund A. Catheter ablation for atrial
fibrillation is associated with lower incidence of stroke and
death: data from Swedish health registries[J]. Eur Heart J,
2016, 37(31):2478-2487.
[12] Kim JG, Lee YS, Kang KW, et al. Comparative occurrence of
ischemic stroke with the rhythm versus rate control strategy in
a national prospective cohort of atrial fibrillation[J]. Korean J
Intern Med, 2021, 36(1):114-123.
[13] Marrouche NF, Brachmann J, Andresen D, et al. Catheter
ablation for atrial fibrillation with heart failure[J]. N Engl J
Med, 2018, 378(5):417-427.
[14] Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of
dronedarone on cardiovascular events in atrial fibrillation[J].
N Engl J Med, 2009, 360(7):668-678.
[15] Kelly JP, DeVore AD, Wu J et al. Rhythm control versus rate
control in patients with atrial fibrillation and heart failure
with preserved ejection fraction: insights from get with
the guidelines-heart failure[J]. J Am Heart Assoc, 2019,
8(24):e011560.
[16] Chen LY, Norby FL, Gottesman RF, et al. Association of
arial fibrillation with cognitive decline and dementia over 20
years: the ARIC-NCS (Atherosclerosis risk in communities
neurocognitive S\study) [J]. J Am Heart Assoc, 2018,
7(6):e007301.
[17] Rivard L, Khairy P. Mechanisms, clinical significance, and
prevention of cognitive impairment in patients with atrial
fibrillatio[J]. Can J Cardiol, 2017, 33(12):1556-1564.
[18] Damanti S, Pasina L, Cortesi L, et al. Atrial fibrillation:
possible influences of rate and rhythm control strategy
on cognitive performance[J]. J Am Geriatr Soc, 2018,
66(11):2178-2182.
[19] Blomstrom-Lundqvist C, Marrouche N, Connolly S, et al.
Efficacy and safety of dronedarone by atrial fibrillation history
duration: Insights from the ATHENA study[J]. Clin Cardiol,
2020, 43(12):1469-1477.
[20] Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate
control and rhythm control in patients with atrial fibrillation J].
N Engl J Med, 2002, 347(23):1825-1833.
[21] Chew D S, Black-Maier E, Loring Z et al. Diagnosis-toablation
time and recurrence of atrial fibrillation following
catheter ablation: a systematic review and meta-analysis of
observational studies[J]. Circ Arrhythm Electrophysio, 2020,
13(4):e008128.
[22] Valembois L, Audureau E, Takeda A et al. Antiarrhythmics
for maintaining sinus rhythm after cardioversion of
atrial fibrillation[J]. Cochrane Database Syst Rev, 2019,
9:CD005049.
[23] Packer DL, Mark DB, Robb RA, et al. Effect of catheter
ablation vs antiarrhythmic drug therapy on mortality, stroke,
bleeding, and cardiac arrest among patients with atrial
fibrillation: the CABANA randomized clinical trial[J]. JAMA,
2019, 321(13):1261-1274.
[24] Cosedis Nielsen J, Johannessen A, Raatikainen P, et al.
Radiofrequency ablation as initial therapy in paroxysmal atrial
fibrillation[J]. N Engl J Med, 2012, 367(17):1587-1595.
[25] Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate
control for atrial fibrillation and heart failure[J]. N Engl J Med,
2008, 358(25):2667-2677.
[26] Wazni OM, Dandamudi G, Sood N, et al. Cryoballoon ablation
as initial therapy for atrial fibrillation[J]. N Engl J Med, 2021,
384(4):316-324.
[27] Andrade JG, Wells GA, Deyell MW, et al. Cryoablation or
drug therapy for initial treatment of atrial fibrillation[J]. N
Engl J Med, 2021, 384(4): 305-315.
[28] Kuck KH, Lebedev DS, Mikhaylov EN, et al. Catheter ablation
or medical therapy to delay progression of atrial fibrillation:
the randomized controlled atrial fibrillation progression trial
(ATTEST)[J]. Europace, 2021, 23(3): 362-369.
[29] Darkner S, Chen X, Hansen J, et al. Recurrence of arrhythmia
following short-term oral AMIOdarone after CATheter
ablation for atrial fibrillation: a double-blind, randomized,
placebo-controlled study (AMIO-CAT trial)[J]. Eur Heart J,
2014, 35(47):3356-3364.
[30] Duytschaever M, Demolder A, Phlips T, et al. PulmOnary
vein isolation With vs. without continued antiarrhythmic
Drug trEatment in subjects with Recurrent Atrial Fibrillation
(POWDER AF): results from a multicentre randomized
trial[J]. Eur Heart J, 2018, 39(16):1429-1437.
备注/Memo
- 备注/Memo:
-
基金项目：上海市卫生健康委员会卫生行业临床研究青年项目
（10411954800）；上海申康医院发展中心临床三年行动计划项目
（SHDC2020CR6012）
通信作者：刘少稳， E-mail: shaowen.liu@hotmail.com
常用功能
统计/Statistics
- 摘要浏览/Viewed2
- 全文下载/Downloads183
- 评论/Comments
